Premature deaths by visceral leishmaniasis in Brazil investigated through a cohort study: A challenging opportunity?

Carregando...
Imagem de Miniatura
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
MAIA-ELKHOURY, Ana Nilce S.
ROMERO, Gustavo Adolfo Sierra
VALADAS, Samantha Y. O. B.
SOUSA-GOMES, Marcia L.
CUPOLILLO, Elisa
RUIZ-POSTIGO, Jose Antonio
ARGAW, Daniel
SANCHEZ-VAZQUEZ, Manuel J.
Citação
PLOS NEGLECTED TROPICAL DISEASES, v.13, n.12, article ID e0007841, 18p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Visceral Leishmaniasis (VL) is the most severe form of leishmaniasis because it can lead to death. In the Americas, 96% of cases are in Brazil, and despite efforts, the fatality rate has increased in the past years. We analyzed deaths associated to VL in Brazil and investigated the factors that could influence on the timeliness of fatal outcome with emphasis on time (tStoD). Methodology The registered deaths by VL were sourced from the Brazilian National Notification System from 2007-2014. Through a retrospective cohort study, univariate and multivariable Cox proportional hazards model analysis were performed and investigated the factors that could influence the time (tStoD). These factors were analyzed through survival models. Results Out of the 1,589 reported deaths, the median for onset of the symptoms and the case notification date (tStoN) is 25 days (10-61), and for date of case notification and death (tNotD) is 9 days (4-17). The time (tStoN) to event investigation for HIV non-infected individuals was 1.4 (1.16-1.68) greater than the HIV positive group. At the same time peri-urban and urban area were 0.83 (0.47-1.44) and 1.33 (1.16-1.52), respectively. The explorations revealed apparent differences between the time to event investigation (both for tStoN and tNotD) and the age at the onset of the symptoms. According to the tStoN the rate of notification is 1.73 times greater in patients under 5 years old at the onset of the clinical symptoms compared to older patients. Conclusion VL patients under 5 years old were diagnosed earlier and had shorter survival. It could mean that in younger population, although properly diagnosed, the fatality pattern might be related to the severity of the disease. Main host characteristics were evaluated, and age and co-infections seem to have an impact in the disease progression.
Palavras-chave
Referências
  1. Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
  2. ANDRADE TM, 1990, J INFECT DIS, V162, P1354, DOI 10.1093/infdis/162.6.1354
  3. BARRAL A, 1986, AM J TROP MED HYG, V35, P732, DOI 10.4269/ajtmh.1986.35.732
  4. Beachy SH, 2011, INT J HYPERTHER, V27, P344, DOI 10.3109/02656736.2011.562873
  5. Belo VS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002982
  6. Brasil. Ministerio da Saude, 2011, NORM MAN TECN A
  7. Brasil. Ministerio da Saude, 2016, COORD GER DES EP SER
  8. Brasil. Ministerio da Saude, SIST INF SINAN CAS C
  9. Brasil. Ministerio da Saude, 2000, SIST INF NOT SINAN L
  10. Brasil. Ministerio da Saude, 2014, NOT INF CGDT DEVIT S
  11. Collin S, 2004, CLIN INFECT DIS, V38, P612, DOI 10.1086/381203
  12. Costa DL, 2016, REV SOC BRAS MED TRO, V49, P728, DOI 10.1590/0037-8682-0258-2016
  13. COX DR, 1972, J R STAT SOC B, V34, P187
  14. de Alvarenga DG, 2010, REV SOC BRAS MED TRO, V43, P194, DOI 10.1590/S0037-86822010000200017
  15. de Sousa-Gomes ML, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005772
  16. Driemeier M, 2015, PATHOG GLOB HEALTH, V109, P283, DOI 10.1179/2047773215Y.0000000029
  17. Gardinassi LG, 2014, MBIO, V5, DOI 10.1128/mBio.01844-14
  18. Góes Marco Aurélio de Oliveira, 2012, Rev. bras. epidemiol., V15, P298, DOI 10.1590/S1415-790X2012000200007
  19. GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
  20. Lindoso JAL, 2006, LEISHMANIOSE VISCERA, V3, P7
  21. de Assis TSM, 2012, TROP MED INT HEALTH, V17, P1202, DOI 10.1111/j.1365-3156.2012.03064.x
  22. Madalosso G, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/281572
  23. Maia-Elkhoury ANS, 2008, CAD SAUDE PUBLICA, V24, P2941, DOI 10.1590/S0102-311X2008001200024
  24. Ferreira GEM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036242
  25. Ministerio da Saude, 2014, MAN VIG CONTR LEISHM
  26. de Araujo VEM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001511
  27. Pan American Health Organization (PAHO), 2016, SER LEISHM REP, V4
  28. Pastorino Antonio C., 2002, J. Pediatr. (Rio J.), V78, P120, DOI 10.1590/S0021-75572002000200010
  29. Queiroz Márcia J. A., 2004, J. Pediatr. (Rio J.), V80, P141, DOI 10.1590/S0021-75572004000200012
  30. Rey Luís C., 2005, J. Pediatr. (Rio J.), V81, P73, DOI 10.1590/S0021-75572005000100014
  31. Romero GAS, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000584
  32. Santos Mácia A., 2002, Rev. Soc. Bras. Med. Trop., V35, P629, DOI 10.1590/S0037-86822002000600014
  33. Santos PL, 2012, NITRIC OXIDE-BIOL CH, V27, P67, DOI 10.1016/j.niox.2012.04.004
  34. Segatto M, 2012, MEM I OSWALDO CRUZ, V107, P39, DOI 10.1590/S0074-02762012000100006
  35. Romero GAS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005706
  36. de Carvalho IPSF, 2017, TROP MED INT HEALTH, V22, P1579, DOI 10.1111/tmi.12994
  37. United Nations, 2015, UN C SUMM EC SOC REL
  38. Weirather JL, 2017, ANN HUM GENET, V81, P41, DOI 10.1111/ahg.12180
  39. Werneck GL, 2003, INFECTION, V31, P174, DOI 10.1007/s15010-003-3139-9
  40. WHO, 2016, WEEKLY EPIDEMIOLOGIC, V91, P285, DOI 10.1186/1750-9378-2-15.VOIR
  41. World Health Organization (WHO) = Organisation mondiale de la Sante (OMS), 2017, GLOB LEISHM UPD 2006, V92, P557
  42. World Health Organization (WHO) = Organisation mondiale de la Sante (OMS), 2002, WKLY EPIDEMIOL REC, V77, P365
  43. Zacarias DA, 2017, TROP MED INT HEALTH, V22, P679, DOI 10.1111/tmi.12877